Skip to main content

Table 1 Comparison of baseline characteristics between the EU and HT groups

From: Hypothyroidism and risks of cerebrovascular complications among patients with head and neck cancer after radiotherapy

  HT group
(N = 122)
EU group
(N = 94)
p
Demographics
 Age (y/o) 56.15 ± 10.40 55.41 ± 9.09 0.58
 Gender (male, %) 78 (63.9 %) 73 (77.7 %) 0.03*
 Hypertension (%) 36 (29.5 %) 37 (39.4 %) 0.13
 Diabetes mellitus (%) 20 (16.4 %) 16 (17.0 %) 0.90
 Smoking (%) 62 (50.8 %) 59 (62.8 %) 0.08
 RT dose (centi-grays) 7021.55 ± 401.67 6869.69 ± 425.32 0.02*
 RT interval (years) 9.18 ± 4.54 8.65 ± 4.48 0.39
 Baseline total plaque scores 3.30 ± 2.91 3.43 ± 3.43 0.78
Laboratory data
 HbA1C (%) 5.90 ± 0.63 5.83 ± 0.56 0.48
 Cr (mg/dL) 0.88 ± 0.27 0.89 ± 0.33 0.80
 LDL (mg/dL) 123.11 ± 41.32 119.78 ± 38.93 0.55
 Triglyceride (mg/dL) 127.70 ± 88.50 132.64 ± 80.03 0.68
 TSH 4.41 ± 3.94 2.33 ± 1.26 < 0.001*
 Free-T4 1.06 ± 0.22 1.10 ± 0.16 0.15
 High-sensitivity CRP 3.30 ± 6.06 3.62 ± 6.45 0.78
Medications
 Anti-platelets (%) 85 (69.7 %) 55 (58.5 %) 0.09
 Statins (%) 19 (15.6 %) 10 (10.6 %) 0.29
Clinical follow-up weeks 190.25 ± 29.00 192.26 ± 33.71 0.64
CDU follow-up weeks 152.39.25 ± 46.38 152.76 ± 42.84 0.95
  1. CDU carotid duplex ultrasound, Cr creatinine, EU euthyroid, HbA1C glycated hemoglobin, HT hypothyroidism, LDL low-density lipoprotein, RT radiation therapy, TSH thyroid stimulating hormone, CRP C-reactive protein; *p < 0.05